Sign In
Buy BPMC
$129.46
+0 (+0%)
At Close: Oct 17, 2025
Blueprint (BPMC) Q1 Earnings and Revenues Beat, Stock Rises
10:56am, Friday, 03'rd May 2024
Blueprint (BPMC) gains from better-than-expected first-quarter 2024 results, driven by robust Ayvakit sales growth. The company raises its revenue guidance for 2024.
Blueprint Medicines Corporation (BPMC) Q1 2024 Earnings Call Transcript
01:42pm, Thursday, 02'nd May 2024
Blueprint Medicines Corporation (NASDAQ:BPMC ) Q1 2024 Earnings Conference Call May 2, 2024 8:00 AM ET Company Participants Jenna Cohen - Vice President-Investor Relations Kate Haviland - Chief Execut
Blueprint Medicines (BPMC) Reports Q1 Loss, Tops Revenue Estimates
09:11am, Thursday, 02'nd May 2024
Blueprint Medicines (BPMC) came out with a quarterly loss of $1.32 per share versus the Zacks Consensus Estimate of a loss of $1.64. This compares to loss of $2.15 per share a year ago.
Blueprint Medicines Reports Strong First Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance
07:00am, Thursday, 02'nd May 2024
-- Achieved $92.5 million in AYVAKIT net product revenues in the first quarter 2024 -- -- Raising guidance to $390 million to $410 million in full year AYVAKIT net product revenues -- -- Strengthenin
Blueprint Medicines (BPMC) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
11:07am, Thursday, 25'th Apr 2024
Blueprint Medicines (BPMC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Blueprint Medicines to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024
08:00am, Thursday, 18'th Apr 2024
CAMBRIDGE, Mass. , April 18, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m.
Blueprint Medicines to Host Webcast and Conference Call Highlighting Emerging Opportunities for Mast Cell-Targeted Therapeutics
08:00am, Thursday, 11'th Apr 2024
� -- Dr. Mariana Castells, M.D., Ph.D., a renowned researcher and clinical expert in mast cell diseases, will join members of Blueprint Medicines' management team to provide a perspective on the mas
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Thursday, 04'th Apr 2024
CAMBRIDGE, Mass. , April 4, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), today announced that, effective April 1, 2024, the Compensation Committee of Blueprint Medicines' Board
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Wednesday, 06'th Mar 2024
CAMBRIDGE, Mass. , March 6, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), today announced that, effective March 1, 2024, the Compensation Committee of Blueprint Medicines' Board
-- AYVAKIT data in patients with indolent systemic mastocytosis show durable efficacy and favorable safety supporting long-term treatment, consistent with real-world experience observed in commercial
Blueprint Medicines: Ayvakit Revenue Surge Fuels Optimism (Rating Upgrade)
12:17pm, Tuesday, 20'th Feb 2024
Blueprint Medicines' Ayvakit shows strong performance in the ISM market, with revenue projections increased to $2 billion. Q4 '23 earnings highlight significant growth, with Ayvakit driving revenues u
Here's What Key Metrics Tell Us About Blueprint Medicines (BPMC) Q4 Earnings
04:31pm, Friday, 16'th Feb 2024
While the top- and bottom-line numbers for Blueprint Medicines (BPMC) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key me
Blueprint (BPMC) Q4 Earnings Beat, Stock Up as Ayvakit Shines
06:51am, Friday, 16'th Feb 2024
Blueprint (BPMC) climbs 14% on better-than-expected fourth-quarter 2023 results, driven by increased Ayvakit sales following the drug's label expansion for the ISM indication.
Blueprint Medicines Corporation (BPMC) Q4 2023 Earnings Call Transcript
01:11pm, Thursday, 15'th Feb 2024
Blueprint Medicines Corporation (BPMC) Q4 2023 Earnings Call Transcript
Blueprint Medicines (BPMC) Reports Q4 Loss, Tops Revenue Estimates
09:26am, Thursday, 15'th Feb 2024
Blueprint Medicines (BPMC) came out with a quarterly loss of $1.82 per share versus the Zacks Consensus Estimate of a loss of $2.04. This compares to loss of $2.65 per share a year ago.
